Shares of Enliven Therapeutics (ELVN) climbed on Thursday after the cancer drug developer posted initial data from a Phase 1b ...
KeifeRx, announced that Chief Executive Officer Chris Hoyt will be speaking at two leading investor events during J.P. Morgan Healthcare Conference week. WASHINGTON, DC, UNITED STATES, January 5, 2026 ...
Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug ...
Alumis (ALMS) stock surged after two Phase 3 trial for its lead drug, envudeucitinib, succeeded against plaque psoriasis.
In both trials, envudeucitinib showed greater skin clearance than placebo on both co-primary endpoints at week 16.
HER2CLIMB-05 trial evaluated Tukysa in combination with Herceptin and Perjeta for HER2-positive metastatic breast cancer, ...
In the phase 2 FASCINATION trial, researchers sought to improve the rate of major molecular response 4 in patients newly diagnosed with CML.
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases ...
Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback